Physician profile
Philippe Armand
NPI 1689648263
$125,658.36
in general payments reported to CMS, 2019-2025
19 companies · $28K in 2025
The $28K reported for 2025 was more than what 94% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $13K · 2021: $22K · 2022: $9,899 · 2023: $10K · 2024: $14K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $48K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,625 · Food and Beverage: $536 · Travel and Lodging: $482 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $454 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $47,696.85 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,625.00 |
| Food and Beverage | $536.05 |
| Travel and Lodging | $481.91 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $453.74 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $47,312.64 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $25,771.20 | 2019-2025 | |
| Genentech, INC. | $15,125.42 | 2020-2022 | |
| Genentech USA, INC. | $6,240.00 | 2021-2024 | Columvi, Polivy, Lunsumio |
| Pfizer INC. | $5,340.00 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $4,989.06 | 2019-2024 | |
| Adc Therapeutics America, INC. | $3,712.00 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $3,604.26 | 2021-2025 | Enhertu |
| Genmab U.S., INC. | $3,446.70 | 2023 | Epkinly |
| Daiichi Sankyo INC. | $2,699.20 | 2019 | |
| Celgene Corporation | $2,103.48 | 2019 | |
| Abbvie INC. | $1,927.26 | 2024-2025 | |
| Epizyme, INC. | $1,812.50 | 2020 | |
| Eli Lilly and Company | $1,200.00 | 2025 | |
| Taiho Oncology, INC. | $224.64 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $150.00 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philippe Armand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.